Why the study?
Does coexisting peripheral artery disease increase the risk of adverse in-hospital outcomes in patients undergoing endovascular transcatheter aortic valve replacement?
Does coexisting peripheral artery disease increase the risk of adverse in-hospital outcomes in patients undergoing endovascular transcatheter aortic valve replacement?
In patients undergoing EV-TAVR, coexisting PAD is present in about 25% of cases and is associated with increased periprocedural morbidity and longer hospital stays, though not in-hospital mortality.
PAD in EV-TAVR signals higher periprocedural morbidity and LOS without mortality increase; leaves open targeted mitigation strategies in this subgroup.
Of patients undergoing EV-TAVR, ~25% have coexisting PAD. PAD was not associated with increased risk of in-hospital mortality but was associated with higher risk of vascular complications, major bleeding, AKI, stroke, cardiac complications, and longer LOS.
No takes yet. Share an insight, caveat, or question.
Mohananey et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: